Retinitis pigmentosa (RP) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting retinitis pigmentosa (rp) clinical trials across 13 countries. Studies span Not Applicable, Phase 2, Phase 1. Top locations include Philadelphia, Pennsylvania, United States, Dallas, Texas, United States, Madison, Wisconsin, United States. Updated daily from ClinicalTrials.gov.


Retinitis pigmentosa (RP) Trials at a Glance

7 actively recruiting trials for retinitis pigmentosa (rp) are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Philadelphia, Dallas, and Madison. Lead sponsors running retinitis pigmentosa (rp) studies include BlueRock Therapeutics, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, and Ace Cells Lab Limited.

Browse retinitis pigmentosa (rp) trials by phase

Treatments under study

About Retinitis pigmentosa (RP) Clinical Trials

Looking for clinical trials for Retinitis pigmentosa (RP)? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinitis pigmentosa (RP) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinitis pigmentosa (RP) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance

Retinitis pigmentosa (RP)Cone-Rod DystrophyUsher Syndrome
Okuvision GmbH30 enrolled1 locationNCT07548944
Recruiting
Not Applicable

Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

Retinitis pigmentosa (RP)Cataract
Zhongshan Ophthalmic Center, Sun Yat-sen University88 enrolled3 locationsNCT07126470
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting
Not Applicable

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Retinitis pigmentosa (RP)Stargardt DiseaseInherited Retinal Degeneration
Science Corporation5 enrolled1 locationNCT07266584
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Not Applicable

Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital

Retinitis pigmentosa (RP)
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts80 enrolled1 locationNCT07292987
Recruiting
Phase 1Phase 2

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Retinitis pigmentosa (RP)Age-Related Macular DegenerationDiabetic Retinopathy
Ace Cells Lab Limited100 enrolled2 locationsNCT06787482